KKR: plans to acquire Immedica Pharma in Sweden

(CercleFinance.com) - KKR announces plans to acquire Immedica Pharma, a Swedish pharmaceutical company specialising in the sale of drugs for rare diseases and specialised care products.


It is expected that Impilo, a Nordic healthcare investment company and current owner of Immedica Pharma, will reinvest to become an equal owner alongside KKR.

The transaction is subject to customary regulatory and closing conditions.

KKR and Impilo will work with Immedica's management team to support the company's continued growth.

Consideration is also being given to expansion into the US prior to regulatory filing and potential approval of Loargys by the US FDA.


Copyright (c) 2024 CercleFinance.com. All rights reserved.